Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-CHOP Alone vs R-CHOP Plus Radiotherapy for Localized CD20+ DLBCL
NCT02054559Phase 3Withdrawn
- Sponsor
- Asan Medical Center
- Primary completion
- Jan 2020
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone in diffuse large B-cell lymphoma (DLBCL), sponsored by Asan Medical Center. Status: withdrawn.
02
Drugs
rituximabcyclophosphamidedoxorubicinvincristineprednisone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02054559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02054559.